1. Home
  2. VTYX vs CGBD Comparison

VTYX vs CGBD Comparison

Compare VTYX & CGBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ventyx Biosciences Inc.

VTYX

Ventyx Biosciences Inc.

HOLD

Current Price

$13.99

Market Cap

990.9M

Sector

Health Care

ML Signal

HOLD

Logo Carlyle Secured Lending Inc.

CGBD

Carlyle Secured Lending Inc.

HOLD

Current Price

$10.75

Market Cap

913.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
VTYX
CGBD
Founded
2018
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
990.9M
913.5M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
VTYX
CGBD
Price
$13.99
$10.75
Analyst Decision
Hold
Hold
Analyst Count
7
7
Target Price
$13.50
$13.50
AVG Volume (30 Days)
3.8M
745.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
15.19%
EPS Growth
40.30
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$3.70
Revenue Next Year
N/A
$1.07
P/E Ratio
N/A
$10.36
Revenue Growth
N/A
N/A
52 Week Low
$0.90
$10.64
52 Week High
$15.34
$17.33

Technical Indicators

Market Signals
Indicator
VTYX
CGBD
Relative Strength Index (RSI) 72.58 33.84
Support Level $13.89 N/A
Resistance Level $14.07 $13.06
Average True Range (ATR) 0.03 0.33
MACD -0.11 -0.01
Stochastic Oscillator 88.89 10.71

Price Performance

Historical Comparison
VTYX
CGBD

About VTYX Ventyx Biosciences Inc.

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

About CGBD Carlyle Secured Lending Inc.

Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.

Share on Social Networks: